We must detect the smoke before it becomes a fire
For the millions living with chronic kidney disease who do not have diabetes, the path forward has long been narrow — blood pressure medications and watchful waiting, while the organ quietly fails. Three landmark studies published this year suggest that finerenone, a drug that quiets the inflammation and scarring common to many forms of kidney disease, may widen that path considerably, offering a shared biological answer to what medicine has long treated as separate conditions. The findings arrive not as a cure but as a meaningful delay — and in the arithmetic of kidney failure, delay is everything.
- Millions of non-diabetic kidney disease patients have had almost no targeted treatment options, watching their organ function erode toward dialysis or transplant with little to slow the decline.
- Three major trials — including FIND-CKD, which followed 1,584 non-diabetic patients over nearly three years — found finerenone consistently slowed kidney function loss and cut the risk of major kidney and heart complications across diverse disease types.
- The drug's power lies not in targeting a single diagnosis but in blocking the inflammation and scarring that damage kidneys regardless of cause, a shared biological pathway that makes it relevant to conditions from IgA nephropathy to focal segmental glomerulosclerosis.
- A real risk exists: about 17 percent of patients developed elevated blood potassium, which can disturb heart rhythm, though severe cases were rare and manageable through routine monitoring.
- In India, finerenone is already available at roughly ₹100 per day — affordable compared to disease-specific therapies costing hundreds of thousands of dollars — with prices expected to fall further after the 2028 patent expiry.
- Researchers warn that treatment access means little without detection first: a simple urine protein test by primary care doctors could catch kidney disease early enough for therapy to make a real difference.
A kidney in decline rarely announces itself. For most patients, the damage comes from diabetes or high blood pressure; for millions of others, it arrives through autoimmune disorders, genetic conditions, or causes medicine has yet to fully name. Once the slide begins, available treatments can slow it — but many patients still watch their function fall year after year, dialysis or transplant looming somewhere ahead.
Three studies published this year in the New England Journal of Medicine, JAMA, and The Lancet suggest that finerenone, developed initially for diabetic kidney disease, works far more broadly than its origins implied. The drug does not act on diabetes itself. Instead, it suppresses the inflammation and scarring that accumulate inside the kidney regardless of what first caused the damage — a mechanism that appears to operate across many different kidney diseases.
The largest trial, FIND-CKD, followed 1,584 non-diabetic patients over nearly three years. Those taking finerenone alongside standard medications lost kidney function more slowly and faced lower risk of major kidney and heart complications than those on placebo. A focused analysis of patients with glomerular diseases — conditions that directly damage the kidney's filtering units, including IgA nephropathy, focal segmental glomerulosclerosis, and membranous nephropathy — found the drug reduced protein leakage in urine by roughly 42 percent and lowered the risk of kidney failure. A third analysis pooled data from over 14,500 patients across multiple trials; the benefits held steady throughout.
Rajiv Agarwal of Indiana University, a co-author of the studies, stressed that the drug's value extends beyond any single diagnosis. Some targeted kidney therapies cost $400,000 to $500,000 annually — sums almost no patient can reach. Finerenone, by contrast, costs around ₹100 per day in India and is expected to become cheaper still after its patent expires in 2028.
The drug carries a meaningful caution: elevated blood potassium, which can disturb heart rhythm, affected about 17 percent of study participants. Severe cases requiring hospitalization were rare, and the risk is manageable through routine blood monitoring — doctors simply do not prescribe it to patients whose potassium is already high.
Agarwal argued, however, that the deeper problem is not treatment but discovery. India's population faces heightened susceptibility to diabetes and hypertension, and many patients learn they have kidney disease only after significant damage has already occurred. A simple urine test for protein leakage can catch the condition when intervention still matters most — but that test has to happen. The physicians best positioned to order it are not nephrologists but family doctors, the ones who see diabetic and hypertensive patients year after year before kidney disease ever enters the conversation. "We must detect the smoke before it becomes a fire," Agarwal said — and now, at least, there is more to reach for once the smoke is found.
A kidney gradually loses its ability to filter waste from blood. For most people, this happens because of diabetes or high blood pressure. But for millions of others, the damage comes from autoimmune disorders, genetic conditions, or causes doctors still don't fully understand. Once the decline begins, current treatments can slow it—blood pressure medications, newer drugs that ease the metabolic burden on the organ—but many patients still watch their kidney function deteriorate year after year, knowing that dialysis or transplant may eventually become inevitable.
That calculus may be shifting. Three major studies published this year in the New England Journal of Medicine, JAMA, and The Lancet suggest that finerenone, a drug developed primarily for diabetic kidney disease, works across a much broader landscape of kidney ailments. The drug does not target diabetes itself. Instead, it quiets the inflammation and scarring that occur inside the kidney regardless of what triggered the damage in the first place—a mechanism that appears to operate across many different forms of kidney disease.
The largest of the three trials, called FIND-CKD, followed 1,584 patients with chronic kidney disease who did not have diabetes. Half received finerenone alongside their usual medications; half received placebo. Over nearly three years, those taking finerenone lost kidney function more slowly and faced lower risk of major kidney or heart complications. In a second analysis of more than 900 participants from the same trial who had glomerular diseases—conditions that directly damage the kidney's filtering units—finerenone reduced protein leakage in urine by roughly 42 percent and lowered the risk of kidney failure. These glomerular diseases included IgA nephropathy, an autoimmune condition, as well as focal segmental glomerulosclerosis and membranous nephropathy, both leading causes of kidney failure worldwide.
Rajiv Agarwal, an emeritus professor of medicine at Indiana University and co-author of the studies, emphasized that the drug's benefits were not confined to any single diagnosis. "Anybody who has glomerulonephritis can use this drug," he said. The point matters because some targeted therapies for specific kidney diseases cost $400,000 to $500,000 annually—sums most patients cannot access. A third analysis combined data from FIND-CKD with two earlier trials, examining 14,574 patients across different kidney diseases and stages. The benefits remained consistent, suggesting finerenone targets a shared biological pathway rather than acting on disease-specific mechanisms.
The drug is not without risk. The primary concern is hyperkalaemia—elevated potassium in the blood, which can trigger dangerous heart rhythm disturbances. About 17 percent of patients in the studies developed elevated potassium levels, though severe cases requiring hospitalization were rare. Doctors can manage this risk through routine blood tests and simply will not prescribe the drug to patients whose potassium is already elevated. In India, where finerenone is already available, the drug costs roughly 80 to 90 rupees daily. Agarwal expects the price to drop significantly after the patent expires in 2028. Even at current prices, he noted, a full course of modern kidney-protective therapy for a diabetic patient costs less than 200 rupees a day in India, while non-diabetic patients might be treated for around 100 rupees daily.
Yet Agarwal argued that the real bottleneck is not treatment but detection. India faces particular pressure: its population appears genetically more susceptible to diabetes and high blood pressure than many Western populations, and both conditions are rising rapidly. Many patients discover they have kidney disease only after substantial damage has already occurred. A simple urine test checking for protein leakage can identify kidney damage at a stage when treatment is most effective—but that test must happen first. "We must detect the smoke before it becomes a fire," Agarwal said. The message carries new weight now that doctors have multiple therapies capable of slowing kidney disease once it is found. The people who will make the difference, he emphasized, are not kidney specialists but primary care physicians, the family doctors who see diabetic and hypertensive patients year after year before they ever reach a nephrologist.
Notable Quotes
Anybody who has glomerulonephritis can use this drug. The alternatives are much more expensive. Some targeted therapies for IgA nephropathy cost $400,000 to $500,000 a year.— Rajiv Agarwal, emeritus professor of medicine at Indiana University
The people who are really going to make a difference are not the nephrologists but the primary care doctors.— Rajiv Agarwal
The Hearth Conversation Another angle on the story
Why does finerenone work across so many different kidney diseases when they seem to have different causes?
Because the damage mechanism is shared. Whether it's diabetes, an autoimmune attack, or genetic scarring, the kidney responds the same way—with inflammation and fibrosis. Finerenone blocks that response, not the original trigger.
So it's like treating the fire instead of the match that started it?
Exactly. The match matters for prevention, but once the fire is burning, you need something that extinguishes the flames themselves.
The potassium risk sounds serious. How many patients will be excluded?
Anyone with baseline potassium above 5 millimoles per litre won't get the drug. That's a meaningful subset, but most people can be monitored with simple blood tests. It's manageable, not a dealbreaker.
You mentioned cost. Is finerenone actually affordable in India right now?
At 80 to 90 rupees a day, it's competitive with other kidney therapies. But the real affordability story begins in 2028 when the patent expires. Generic versions could make it accessible to millions more.
If the drug works, why does Agarwal keep talking about early detection?
Because the drug can only slow disease, not reverse it. If you catch kidney damage when function is still 80 percent, treatment works. If you wait until it's 20 percent, you've already lost too much. Detection is the gate that opens everything else.